Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes

40Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

This study assessed the single- and multiple-dose pharmacokinetics of 3 doses (15 mg, 30 mg, and 45 mg) of pioglitazone in 36 adolescents with type 2 diabetes. Blood samples were obtained over a 48-hour interval after the first dose (day 1) and over a 72-hour interval after the last dose (day 15) of pioglitazone and were assayed for pioglitazone and active metabolites (M-III and M-IV). Pioglitazone systemic exposure increased dose dependently but was less than dose proportional during multiple dosing. The median peak pioglitazone concentration occurred at 2 hours. The mean half-life was 8 to 9 hours for pioglitazone and 24 to 32 hours for M-III and M-IV, with similar values at each dose level. During multiple dosing, accumulation for pioglitazone was negligible, but it reached 2.5- to 3.0-fold for M-III and M-IV. The sustained total serum concentration of active compounds during multiple dosing provides the basis for once-daily dose administration of pioglitazone in adolescents. ©2005 the American College of Clinical Pharmacology.

Cite

CITATION STYLE

APA

Christensen, M. L., Meibohm, B., Capparelli, E. V., Velasquez-Mieyer, P., Burghen, G. A., & Tamborlane, W. V. (2005). Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. Journal of Clinical Pharmacology, 45(10), 1137–1144. https://doi.org/10.1177/0091270005279578

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free